MedElevator
Войти в исследования Current opinion in supportive and palliative care · 2025
Cough and dyspnea management in pulmonary fibrosis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Veelen Allard, Wijsenbeek Marlies S, Koudstaal Thomas
Аннотация
PURPOSE OF THE REVIEW: Pulmonary fibrosis (PF) is characterized by relentless scarring of the lungs, declining lung function, and increasing symptom burden. In PF, dyspnea and cough are the most common symptoms, severely impacting quality of life. This review highlights recent advances in understanding their mechanisms and explores evolving strategies for management of these symptoms.
RECENT FINDINGS: Advances in non-pharmacologic approaches, including hand-held fans, dyspnea services and pulmonary rehabilitation are playing a vital role in dyspnea management. Opioids, while effective in reducing exertional dyspnea in controlled settings, show limited benefit for daily life breathlessness and are associated with significant adverse events, highlighting the need for cautious, individualized use. For refractory cough, promising studies are investigating the role of opioids and neuromodulatory therapies. Non-pharmacologic approaches, including speech therapy, and behavioral interventions, provide complementary approaches. A multidisciplinary approach and individualized care plans to address the multifactorial nature of dyspnea and cough are key.
SUMMARY: Effective management of dyspnea and cough can importantly improve patients' quality of life. Further research is required to refine treatment protocols, optimize palliative care interventions, and identify and test novel therapeutics. Translation of these findings into clinical practice requires a focus on evidence-based, patient-centered care.
RECENT FINDINGS: Advances in non-pharmacologic approaches, including hand-held fans, dyspnea services and pulmonary rehabilitation are playing a vital role in dyspnea management. Opioids, while effective in reducing exertional dyspnea in controlled settings, show limited benefit for daily life breathlessness and are associated with significant adverse events, highlighting the need for cautious, individualized use. For refractory cough, promising studies are investigating the role of opioids and neuromodulatory therapies. Non-pharmacologic approaches, including speech therapy, and behavioral interventions, provide complementary approaches. A multidisciplinary approach and individualized care plans to address the multifactorial nature of dyspnea and cough are key.
SUMMARY: Effective management of dyspnea and cough can importantly improve patients' quality of life. Further research is required to refine treatment protocols, optimize palliative care interventions, and identify and test novel therapeutics. Translation of these findings into clinical practice requires a focus on evidence-based, patient-centered care.